OMIC
NASDAQSingular Genomics Systems Inc.
Website
News25/Ratings5
Latest news
25 items- INSIDERLarge owner Tang Kevin returned 372,000 shares to the company (SEC Form 4)4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)
- SECSingular Genomics Systems Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Material Modification to Rights of Security Holders, Changes in Control of Registrant8-K - Singular Genomics Systems, Inc. (0001850906) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Singular Genomics Systems Inc.SCHEDULE 13D/A - Singular Genomics Systems, Inc. (0001850906) (Subject)
- INSIDERChief Executive Officer Spaventa Andrew returned 143,310 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)
- INSIDERChief Financial Officer Meeter Dalen returned 9,502 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)
- INSIDERChief Scientific Officer Glezer Eli N. returned 155,583 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)
- INSIDERChief Operating Officer Ghai Jyotsna returned 3,283 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)
- INSIDERSEC Form 4 filed by Director Ryan Jason4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)
- INSIDERDirector Pellini Michael J returned 351,222 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)
- INSIDERSEC Form 4 filed by Director Mardis Elaine R4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)
- INSIDERDirector Kamdar Kim P. returned 3,793,985 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)
- INSIDERSEC Form 4 filed by Director Eisenberg Marcia4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)
- INSIDERDirector Barker David L returned 1,060,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)
- PRSingular Highlights Key G4X™ Launch Milestones and Showcases Groundbreaking 3D Spatial Multiomic Performance at AGBTSAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc., an innovator in high-throughput spatial multiomics technologies designed to advance precision medicine, today announced key development milestones for its G4X™ Spatial Sequencer at the Advances in Genome Biology and Technology (AGBT) conference in Marco Island, Florida. G4X Early Access Program Ongoing and Broader Availability on Track The G4X Early Access Program is currently underway at Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center, providing valuable feedback highlighting the platform's real-world potential. "As the first early access site, we've had the chance to
- SECSEC Form EFFECT filed by Singular Genomics Systems Inc.EFFECT - Singular Genomics Systems, Inc. (0001850906) (Filer)
- PRSingular Genomics Announces Closing of Acquisition by Deerfield ManagementSAN DIEGO, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today the closing of its acquisition by an affiliate of Deerfield Management Company, L.P. On December 23, 2024, Singular Genomics announced that Deerfield had signed a definitive agreement to acquire all of the outstanding shares of Singular Genomics common stock not currently owned by Deerfield for $20.00 per share in cash. Following the satisfaction of customary conditions, including a vote of the holders of Singular Genomics' common stock to approv
- SECSEC Form 25-NSE filed by Singular Genomics Systems Inc.25-NSE - Singular Genomics Systems, Inc. (0001850906) (Subject)
- SECSEC Form S-8 POS filed by Singular Genomics Systems Inc.S-8 POS - Singular Genomics Systems, Inc. (0001850906) (Filer)
- SECSEC Form S-8 POS filed by Singular Genomics Systems Inc.S-8 POS - Singular Genomics Systems, Inc. (0001850906) (Filer)
- SECSEC Form S-8 POS filed by Singular Genomics Systems Inc.S-8 POS - Singular Genomics Systems, Inc. (0001850906) (Filer)
- SECSEC Form S-8 POS filed by Singular Genomics Systems Inc.S-8 POS - Singular Genomics Systems, Inc. (0001850906) (Filer)
- SECSEC Form S-8 POS filed by Singular Genomics Systems Inc.S-8 POS - Singular Genomics Systems, Inc. (0001850906) (Filer)
- SECSEC Form POS AM filed by Singular Genomics Systems Inc.POS AM - Singular Genomics Systems, Inc. (0001850906) (Filer)
- SECSEC Form 8-K filed by Singular Genomics Systems Inc.8-K - Singular Genomics Systems, Inc. (0001850906) (Filer)
- INSIDERChief Executive Officer Spaventa Andrew converted options into 1,907 shares, sold $15,912 worth of shares (800 units at $19.89), gifted 1,107 shares and received a gift of 1,107 shares (SEC Form 4)4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)